Volume 16, Issue 2 (volume 16, number 2 2024)                   IJDO 2024, 16(2): 122-126 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Roy D, Gayen G, Ara Begum S, Ghosh S, Talukder S, Sarkar A et al . Vildagliptin-Associated Bullous Pemphigoid: A Case Report. IJDO 2024; 16 (2) :122-126
URL: http://ijdo.ssu.ac.ir/article-1-874-en.html
Multidisciplinary Research Unit, R.G. Kar Medical College and Hospital, Kolkata, India.
Abstract:   (77 Views)

 Objective: Bullous pemphigoid is a rare autoimmune skin disorder characterized by blistering, urticarial lesions, which are sometimes associated with adverse drug reactions.
Vildagliptin is an oral anti-diabetic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme.
Materials and Methods: A 75-year-old female with a known case of type 2 Diabetes Mellitus, hypertension, and hypothyroidism for the last 10 years presented with pruriginous tense bullous skin lesions over her both palms and soles. There was no mucosal involvement. Further interrogation revealed that she started taking Vildagliptin 5 days ago which was prescribed due to high levels of post-prandial blood sugar level despite already intake of Glimepiride-4 mg and Metformin-3 gm.
Results: Vildagliptin was immediately advised to be stopped. She was treated with antihistamines, steroids, and conservative management which led to remission of the blisters.
Conclusion: Vildagliptin is the probable causative drug for developing bullous pemphigoid skin lesion which shows temporal association in this case as other concomitant drugs has no direct correlation. Therefore physicians must be aware of this rare life-threatening side effect of this medicine and advice patients to visit the hospital even the slightest cutaneous manifestation. Bullous pemphigoid can result in fatal life-threatening conditions if not treated early.
Full-Text [PDF 538 kb]   (45 Downloads)    
Type of Study: Research | Subject: Special
Received: 2023/12/24 | Accepted: 2024/04/8 | Published: 2024/06/21

1. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends in immunology. 2008;29(6):295-301. [DOI:10.1016/j.it.2008.02.010]
2. Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Frontiers in immunology. 2019;10:463593. [DOI:10.3389/fimmu.2019.01238]
3. Varpuluoma O, Försti AK, Jokelainen J, Turpeinen M, Timonen M, Huilaja L, Tasanen K. Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study. Journal of Investigative Dermatology. 2018; 138(7):1659-61. [DOI:10.1016/j.jid.2018.01.027]
4. Plaquevent M, Tétart F, Fardet L, Ingen-Housz-Oro S, Valeyrie-Allanore L, Bernard P, et al. Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population. Journal of Investigative Dermatology. 2019;139(4):835-41. [DOI:10.1016/j.jid.2018.10.045]
5. Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. Anais brasileiros de dermatologia. 2019;94:133-46. [DOI:10.1590/abd1806-4841.20199007]

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Diabetes and Obesity

Designed & Developed by : Yektaweb